Precision NanoSystems, Inc. (PNI) today announced that Daiichi Sankyo Company, Limited (Daiichi Sankyo) has signed a license and supply agreement to obtain access to PNI’s NanoAssemblr GMP System. Daiichi Sankyo is a customer of PNI using the NanoAssemblr suite of instruments including the Benchtop and the Blaze to perform research and development with plans to progress towards clinic.
Daiichi Sankyo is a global research-based pharmaceutical company creating innovative medicines to address unmet medical need and is developing new methods for drug discovery and delivery. Daiichi Sankyo uses the NanoAssemblr platform as it offers a turnkey solution to making nanoparticle-based therapeutics under conditions are uniform, controlled and reproducible leading to faster development times, easier to scale up and leading to higher production yields.
With over 280 systems placed worldwide, PNI's proprietary microfluidics technology, the NanoAssemblr platform is the de-facto platform used by over 95 pharma/biotech and 90 academic customers in the areas of gene and cell therapy, rare diseases, immuno-oncology and more. “With the instruments, reagents and services developed by PNI I believe we are well positioned to impact the next wave of pharma manufacturing in nanoparticle-based therapeutics. I look forward to PNI working with Daiichi Sankyo in configuring a customized microfluidics-based GMP System that is fit-for-purpose and stage appropriate.” said James Taylor, co-founder and CEO of PNI.
About Precision NanoSystems Inc.
Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology.